Viridian Therapeutics (NASDAQ:VRDN) Receives “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research note published on Wednesday,Benzinga reports. They currently have a $34.00 price target on the stock. Separately, Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a […]
HC Wainwright reaffirmed their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research note published on Wednesday,Benzinga reports. They currently have a $34.00 price target on the stock. Separately, Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a […]
